Psilocybin + CBT for Depression
This trial studies how combining psilocybin (a psychedelic) with therapy helps treat depression. Two doses of psilocybin are given during 12 therapy sessions, and participants are followed for 4 months.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2021 Phase 2 trial • 95 Patients • NCT02061293
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
May seniors aged 70 or younger join this experiment?
"Per the study's specifications, participants must be between 21 and 60 years old. Separately, there are 121 trials targeting minors and 630 for elderly patients."
Is it currently feasible to enroll in this research project?
"According to clinicaltrials.gov, this medical research project is no longer actively searching for volunteers; it was initially posted on June 27th 2023 and last modified on July 11th 2023. However, 876 other trials are still open for recruitment at present."
Is participation in this research endeavor open to me?
"This clinical trial is enrolling 30 adults between the ages of 21 and 60 who have been diagnosed with depression. In addition to meeting this requirement, applicants must be able to swallow capsules, present current major depressive episodes or a history thereof based on DSM-5 guidelines (American Psychiatric Association 2013), display active symptoms as measured by Hamilton-Depression Rating Scale scores higher than 16 over the last two weeks(Hamilton 1986), identify an individual that can pick them up from UCLA Semel Institute following psilocybin sessions, use one form of highly effective contraception such as oral contraceptive pills if applicable and commit to continuing its use for the duration of their"